ACG Releases New Idiosyncratic Drug-Induced Liver Injury Guidelines
released new clinical guidelines for the diagnosis and treatment of idiosyncratic drug-induced liver injury.
The guidelines include an overview of risk factors, diagnostic tools, casualty assessment, prognosis factors and management of hepatotoxicity. DILI incidence is on the rise and the guidelines are designed to help physicians diagnose and manage the rare, difficult-to-diagnose adverse drug reaction.
The guidelines focus on herbal and dietary supplements due to the overall lack of regulation. Traces of heavy metals and prescription drugs have been found in some herbal and dietary supplements, according to guidelines co-author Herbert L. Bonkovsky, MD, FACG.
More Articles on Gastroenterology:
Can Independent GI Practices Survive & Thrive?
11 GI-Driven ASCs & Facilities Opened in 2014
Mayo Clinic Winds Award for Cologuard: 5 Things to Know
© Copyright ASC COMMUNICATIONS 2014. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
New From Becker's GI & Endoscopy
Can probiotics reduce liver disease in cirrhosis patients? Study says yesRead Now
- Consumer and clinician opinions on big data, telehealth and mHealth: 8 things to know
- Innovation's moral quandary: When am I obligated to reinvent the wheel?
- House Republicans sue Obama administration over PPACA: 5 things to know
- Just 1% of organizations will eliminate healthcare coverage, survey finds
- DOJ recovers $2.3B in healthcare False Claims Act cases in FY 2014